Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer

Table 4 Clinical trials of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor-mutated non-small cell lung cancer who failed chemotherapy

Ref.	EGFR-TKI	Number ofpatients	Responserate (%)	Time to progression (mo)
Sutani et al[21]	Gefitinib	23	74	9.4
Han et al[22]	Gefitinib	17	64	21.7
Cortes-Funes et al[23]	Gefitinib	10	60	12.3
Kim et al[24]	Erlotinib	8	63	NR
Ahn et al[25]	Erlotinib	78	58	8.6

EGFR-TKIs: Epidermal growth factor receptor tyrosine kinase inhibitors; NSCLC: Non-small cell lung cancer; NR: Not reached.